HESPERETIN AMELIORATES ISOPROTERENOL INDUCED CARDIAC HYPERTROPHY: ROLE OF NF?B PATHWAY
Velusamy Prema, Mohan Thangarajeswari, Ravi Divya Bhavani, Srinivasan Ashokkumar, Chakrapani Lakshmi Narasimhan, Singh Abhilasha, Narasimhan Kishore Kumar, Arun Shruthi, Biswas Sapna, Periandavan Kalaiselvi*
ABSTRACT
Latest epidemiological data has revealed that cardiac hypertrophy is a major predictor of heart failure, with a mortality as high as 80% for men and 70% for women within 8 years. Therefore, it is inevitable to develop therapeutic strategies that aim at modulating the hypertrophic remodeling of the heart by modulating inflammatory pathways. Cardiac hypertrophy was induced by subcutaneous injections of isoproterenol (5 mg/kg body weight) for seven days. Rats were pre-treated with hesperetin 30mg/kg body weight suspended in 0.5% methyl cellulose orally for 30 days. The HW/BW ratio, fetal gene expression and macromolecular damage were found to be increased in the isoproterenol administered rats, whereas, hesperetin treated rats showed a decline in the HW/BW ratio and fetal gene expression. The protein expression of inflammatory marker NF-κB was found to be decreased in the hesperetin treated rats when compared to the isoproterenol administered rats. This study suggests NF-κB as a potential target for anti-inflammatory therapy for cardiac hypertrophy and hesperetin modulated NF-κB expression, it therefore could be useful as an anti-inflammatory agent against cardiac hypertrophy.
Keywords: Cardiac hypertrophy, Hesperetin, NF-?B, Inflammation, TNF-?.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
